Table 1.
Functional parameters, infarct size and arrhythmia parameters of the three treatment groups
| Characteristic | Total group (n = 164) | BMMC (n = 60) | PBMC (n = 53) | Control (n = 51) | BMMC vs. Control | PBMC vs. Control | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| p-value | p-value | |||||||||
| Functional and infarct mass parameters | ||||||||||
| Days between primary PCI and MRI | 3(3–4) | 3(2–4) | 3(3–4) | 3(3–5) | 0.79 | 0.81 | ||||
| End-diastolic volume (ml•m-2) | 98 ± 16 | 97 ± 14 | 98 ± 16 | 100 ± 17 | 0.39 | 0.50 | ||||
| End-systolilc volume (ml•m-2) | 57 ± 15 | 55 ± 15 | 57 ± 15 | 59 ± 15 | 0.20 | 0.37 | ||||
| Left ventricular ejection fraction (%) | 43 ± 9 | 44 ± 9 | 43 ± 8 | 41 ± 8 | 0.14 | 0.37 | ||||
| Infarct mass (% of LV mass) | 19% ± 9% | 19% ± 10% | 18% ± 9% | 20% ± 10% | 0.57 | 0.30 | ||||
| Arrhythmia parameters | ||||||||||
| Duration of Holter (hours) at 1 month | 24(23–25) | 24(23–25) | 24(23–24) | 24(23–26) | 0.76 | 0.052 | ||||
| QRS duration (ms) at 1 month | 94(86–100) | 92(83–100) | 94(87–100) | 96(88–100) | 0.08 | 0.32 | ||||
| Corrected QT interval (QTc) at 1 month | 420 ± 27 | 418 ± 29 | 418 ± 28 | 423 ± 24 | 0.37 | 0.33 | ||||
| Serum sodium level (mMol•l-1) at 1 month | 141 ± 2 | 141 ± 2 | 141 ± 2 | 142 ± 2 | 0.40 | 0.01 | ||||
| Serum potassium level (mMol•l-1) at 1 month | 4.3 ± 0.3 | 4.4 ± 0.4 | 4.3 ± 0.3 | 4.3 ± 0.3 | 0.55 | 0.87 | ||||
| Class II anti-arrhythmic drug use during Holter (%) | 157 | 96% | 55 | 92% | 49 | 92% | 50 | 98% | 0.22 | 0.36 |
| Patients with triplet PVCs (%) | 27 | 16% | 9 | 15% | 10 | 19% | 8 | 16% | 0.92 | 0.67 |
| Patients with ventricular tachycardias (>4 PVCs) (%) | 29 | 18% | 9 | 17% | 11 | 21% | 9 | 15% | 0.70 | 0.69 |
| Patients with both triplet PVCs and ventricular tachycardias (%) | 13 | 8% | 4 | 7% | 6 | 11% | 3 | 6% | 1.00 | 0.49 |
| No. of triplet PVCs/24 h (when present) | 1 | (1–3) | 2 | (1–4) | 1 | (1–1) | 2 | (1–3) | 0.74 | 0.42 |
| No. of ventricular tachycardias (when present) | 1 | (1–3) | 1 | (1–3) | 2 | (1–3) | 1 | (1–3) | 0.69 | 0.73 |
BMMC = Bone marrow-derived mononuclear cells, PBMC = peripheral blood-derived mononuclear cells, PCI = percutaneous coronary intervention. P-values are calculated by comparing treatment group vs. control. Data presented as mean ± standard deviation or as median (interquartile range)